SynthesisAmerican journal of obstetrics and gynecology2012
Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.
Synthesis in American journal of obstetrics and gynecology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Pooled it
- Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Spontaneous rupture of a mucinous borderline ovarian tumour in late pregnancy: a case report.Frontiers in oncology · 2026Article
- Article
- Development and validation of a novel combinational index of liquid biopsy biomarker for longitudinal lung cancer patient management.The journal of liquid biopsy · 2024Article
- The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation.Journal of gynecologic oncology · 2024Article
- Diagnostic role of urine human epididymis protein 4 in ovarian cancer.Biochemia medica · 2024Review
- Tumor biomarkers HE4 and CA125 alongside enhanced computed tomography imaging in assessing lymph node metastasis in endometrial cancer.Bioinformation · 2024Article
- Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.Journal of cancer research and clinical oncology · 2023Article
- Review
- Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features.Diagnostics (Basel, Switzerland) · 2022Article
- HE4 Tissue Expression as A Putative Prognostic Marker in Low-Risk/Low-Grade Endometrioid Endometrial Cancer: A Review.Current oncology (Toronto, Ont.) · 2022Review
- Effect of Serum Level of Human Epididymis Protein 4 and Interleukin-6 as Biomarkers in Patients with Adnexal Mass.Archives of Razi Institute · 2022Article
- The Association between Human Epididymis Secretory Protein 4 and Metabolic Syndrome.Journal of clinical medicine · 2022Article
- Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors.Diagnostics (Basel, Switzerland) · 2022Article
- Nanomaterial-based biosensor developing as a route toward in vitro diagnosis of early ovarian cancer.Materials today. Bio · 2022Article
- Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2021Article
- Current clinical application of serum biomarkers to detect and monitor ovarian cancer - update.Przeglad menopauzalny = Menopause review · 2021Review
- HE4 as a Biomarker for Endometrial Cancer.Cancers · 2021Review
- Influence of Pregnancy-Related Conditions on Human Epididymis Protein 4 Serum Levels in Comparison to CA 125 - a Prospective Cohort Trial.Geburtshilfe und Frauenheilkunde · 2021Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveThe purpose of this study was to establish normal ranges for human epididymis protein 4 (HE4) serum levels in healthy women. STUDY
designHE4 levels were measured in healthy women and analyzed by age, menopausal status, and pregnancy status. Upper 95th percentiles were determined for normal ranges.
resultsSerum samples from 1101 healthy women and 67 pregnant women were analyzed. Above the age of 40 years significant elevations in HE4 concentrations emerged with advancing age. The upper 95th percentile for HE4 levels was 89 pmol/L for premenopausal women, 128 pmol/L for postmenopausal women, and 115 pmol/L for all women. There was a significant difference in the median serum HE4 levels in premenopausal women (46.6 pmol/L) compared with postmenopausal women (57.6 pmol/L; P < .001). In pregnant women, median HE4 concentrations were significantly lower than their premenopausal counterparts (P < .001).
conclusionHE4 serum concentrations vary significantly on the basis of age. These variations must be considered when the upper limit of normal for HE4 is determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.